Motley Fool YouTube

Shopify's integrated e-commerce toolbox may turn today's SaaS sell-off into a valuation opportunity.

Why SoFi's future hinges on bank‑style metrics like cross‑sell, CAC payback, and net interest margin.

Could FedEx be the stock that outperforms the market? Join us as we analyze its strengths, weaknesses, and future potential in this insightful episode of Scoreboard.

Vertex dominates cystic fibrosis and has a debt-free balance sheet, but can its pipeline restore faster growth? See why our analysts gave the stock a strong 7.3 out of 10.

Credo Technology is riding the AI infrastructure boom, but how much upside is already priced in? See how our analysts rate the business, management, financials, valuation, and risk.

Docusign is still growing, profitable, and surprisingly cheap--but its moat may be vulnerable. See why our analysts scored the stock 6.7 out of 10 and both prefer Adobe.

Is Cava the next big thing in fast-casual dining? Join us as we explore its strengths, management, and financials to see if this stock is worth your investment.

Join us as we explore Axon, a company at the forefront of law enforcement technology. With strong ratings from our analysts, find out if this stock is a hidden gem worth your investment.

Is ZETA Global the next big opportunity in marketing tech? Join us as we evaluate its strengths, financials, and potential for growth in this insightful episode.

Could On Holding be the next big player in the athletic footwear market? Join us as we dissect its strengths, weaknesses, and future potential in this insightful episode.

Why Pitney Bowes' shrinking sales may still unlock growing profits and free cash flow.

Can Turning Point Brands defend its nicotine pouch niche as Big Tobacco crowds in?

How to choose between a 401(k) and a 457 for unused leave payout at retirement.

How capital gains really affect your tax bracket, AGI, and hidden costs like Medicare premiums.

Test-drive your retirement spending while working to ease anxiety and protect your nest egg.

AI fears hit Synopsys and Cadence, but EDA moats may make this sell-off a buying opportunity.

IBM's plunge looks like a stumble, not a collapse, but investors should wait for clearer AI guidance.

Why CEOs who fixate on short-sellers may signal risk--and what hedging flows really mean.

Could Moderna be the next big opportunity in biotech? Join our experts as they dissect the company's strengths and weaknesses, revealing insights that could shape your investment strategy.

Join us as we dissect Celestica's potential in the rapidly growing AI infrastructure sector. Is this stock a hidden gem or a risky bet? Tune in to find out!